
Associate Professor David Peter Kao
University of Colorado Anschutz Medical Campus, Aurora (United States of America)
Membership:
ESC Professional Member
HFA Member
Biography
Dr. Kao is an academic cardiologist and Medical Director of the Colorado Center for Personalized Medicine (CCPM) and of UCHealth CARE Innovation Center. He studied biomedical engineering and graduated from medical school at the Johns Hopkins University followed by internal medicine residency and biomedical informatics research fellowship at Stanford. He moved to Colorado in 2008 for cardiology fellowship and subsequently joined the faculty. He has been involved in biomedical research since 1996 and has > 100 peer-reviewed publications and holds the Jacqueline Marie Schauble Leaffer Endowed Chair in Women’s Heart Disease. He uses his clinical experience and informatics expertise to combine and leverage very large clinical datasets in order to close critical gaps in knowledge regarding presentation, natural history and management of congestive heart failure with a specific focus on women with HF. He has been a part of the UCHealth electronic health record and digital health teams as wel
Contributor content
Presentation
Latent class analysis of echocardiographic phenotypes predicts adverse outcomes and treatment response in heart failure with preserved ejection fraction
Presentation
Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas
Presentation
Latent class echocardiographic phenotypes predict adverse outcomes in heart failure with preserved ejection fraction: A secondary analysis of TOPCAT
Presentation
Sex differences in long-term health status in heart failure with preserved ejection fraction
Presentation
Heart rate reduction or ventricular reverse remodeling associated with beta-blocker therapy is accompanied widespread, distinct changes in the beta1-adrenergic receptor gene signaling network
Presentation
Association of anemia and transfusion with adverse outcomes in 22,991 patients hospitalized with takostsubo cardiomyopathy
Presentation

